Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients With Post-resection R0/R1 Pancreatic Cancer With Tumor Sequence Confirmation of Ras Mutations.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hyderabad, India, 500034
- Indo American Cancer Hospital and Research Centre
-
Mangalore, India, 575001
- KMC Hospital
-
Nagpur, India
- Govt Medical Colleg & Hospital
-
Nettoor, Cochin, India, 682304
- Lake Shore Hospital & Research Centre
-
New Delhi, India, 110002
- G B Pan Hospital & Maulana Azad Medical College
-
Panjagutta, Hyderaba, India, 500082
- Nizam's Institute of Medical Sciences
-
Perungudi, Chennai, India, 600096
- Lifeline multispecialty Hospital
-
Trivandrum, India, 695011
- Regional Cancer Centre
-
-
Tamil Nadu
-
Peelamedu, Coimbatore, Tamil Nadu, India, 641004
- PSG Hospitals
-
Ponur, Chennai, Tamil Nadu, India, 600116
- Sri ramchandra Medical College & Research Institute
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
Beverly Hills, California, United States, 90211
- Tower Cancer Research Foundation
-
LaJolla, California, United States, 92093
- University of California San Diego
-
Los Angeles, California, United States, 90095
- UCLA Medical Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center / Lombardi Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical School
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Minnesota Oncology Hematology, PA
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
Stony Brook, New York, United States, 11794
- State University of NY at Stony Brook
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Texas
-
Dallas, Texas, United States, 75231
- Texas Oncology, PA
-
Dallas, Texas, United States, 75237
- The Texas Cancer Center Dallas Southwest
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
San Antonio, Texas, United States, 78229
- South Texas Oncology & Hematology
-
Tyler, Texas, United States, 75702
- Tyler Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Multi-Disciplinary Cancer Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
(A few general items required)
Inclusion Criteria:
- Patients with non-metastatic pancreas cancer post-resection that have a product-related ras mutation
- >18 years of age
- Negative skin test for hypersensitivity to Saccharomyces cerevisiae
Exclusion Criteria:
- Metastatic pancreas cancer patients post-resection
- Patients with no product-related ras mutation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1
Gencitabine
|
Heat-killed yeast cell transfected with target ras mutation.
|
|
Experimental: 2
Gemcitabine with GI-4000
|
Chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recurrence free time and survival
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
Other Study ID Numbers
- GI-4000-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.